0.6892
Schlusskurs vom Vortag:
$0.6823
Offen:
$0.6816
24-Stunden-Volumen:
70,988
Relative Volume:
0.45
Marktkapitalisierung:
$47.74M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.7574
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
-4.71%
1M Leistung:
+8.03%
6M Leistung:
-36.77%
1J Leistung:
-32.43%
Cue Biopharma Inc Stock (CUE) Company Profile
Firmenname
Cue Biopharma Inc
Sektor
Branche
Telefon
617-949-2680
Adresse
40 GUEST STREET, BOSTON, MA
Vergleichen Sie CUE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CUE
Cue Biopharma Inc
|
0.6721 | 47.74M | 9.53M | -44.61M | -38.32M | -0.91 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
455.44 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
544.84 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.33 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
555.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.94 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-03-13 | Eingeleitet | Jefferies | Buy |
2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
2022-11-21 | Eingeleitet | Piper Sandler | Overweight |
2022-01-13 | Eingeleitet | H.C. Wainwright | Buy |
2022-01-03 | Eingeleitet | Craig Hallum | Buy |
2020-11-24 | Eingeleitet | Berenberg | Buy |
2020-04-09 | Eingeleitet | Stifel | Buy |
2020-01-28 | Eingeleitet | BTIG Research | Buy |
2020-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Millennium Management LLC Reduces Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Bank of America Corp DE Acquires 85,113 Shares of Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
CueBiopharma (CUE) Appoints Interim CFO as Kerri-Ann Millar Resi - GuruFocus
Cue Biopharma CFO Kerri-Ann Millar to Depart - marketscreener.com
Cue Biopharma CFO Resignation and Board Appointment - TipRanks
Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO - marketscreener.com
Jane Street Group LLC Has $70,000 Stock Holdings in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by Northern Trust Corp - Defense World
Stifel Financial Corp Grows Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Transcript : Cue Biopharma, Inc.Special Call - marketscreener.com
Cue Biopharma Inc Reports Q1 2025 Earnings: EPS of -$0.17 Misses Estimate, Revenue Falls Short at $0.4 Million - GuruFocus
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cue Biopharma (CUE) Reports Revenue Miss for Q1 2025 | CUE Stock News - GuruFocus
Cue Biopharma Reports Strategic Collaboration with Boehringer Ingelheim and Financial Results for Q1 2025 - Nasdaq
Cue Biopharma (CUE) Schedules Virtual Investor Event to Showcase Biologics Platform | CUE Stock News - GuruFocus
Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - The Manila Times
Cue Biopharma to Participate in Fireside Chat at the Citizens Li - GuruFocus
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - The Manila Times
Cue Biopharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
LPL Financial LLC Has $47,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
CUECue Biopharma Inc Latest Stock News & Market Updates - Stock Titan
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Finanzdaten der Cue Biopharma Inc-Aktie (CUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):